Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06389422
Status:
RECRUITING
Last Update Posted:
2024-04-29
First Post:
2024-04-24
Brief Title:
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-24
First Submit QC Date:
April 24 2024
Study First Post Date:
2024-04-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-24
Last Update Post Date:
2024-04-29
Last Update Post Date Type:
ACTUAL